Bio-Techne (TECH) Total Liabilities (2009 - 2026)
Bio-Techne (TECH) posted quarterly Total Liabilities of $2.6 billion for Q1 2026, down 3.54% year-over-year from $2.6 billion in Q1 2025, and up 1.11% quarter-over-quarter from $2.5 billion in Q4 2025.
Analysis
Bio-Techne (TECH) Total Liabilities (2009 - 2026) Analysis & Trends
Bio-Techne's Total Liabilities history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.
- In Q1 2026, Total Liabilities fell 3.54% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (down 3.54% YoY), while the FY2025 annual figure was $2.6 billion, down 5.4% from the prior year.
- Total Liabilities for Q1 2026 stood at $2.6 billion, up from $2.5 billion in the prior quarter.
- The five-year high for Total Liabilities was $2.8 billion in Q3 2023, with the low at $2.3 billion in Q2 2022.
- The 5-year median for Total Liabilities is $2.6 billion (2023), against an average of $2.6 billion.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities advanced 17.21% in 2023, then declined 7.67% in 2025.
- Bio-Techne's Total Liabilities stood at $2.4 billion in 2022, then advanced by 15.54% to $2.7 billion in 2023, then declined by 2.21% to $2.7 billion in 2024, then fell by 5.53% to $2.5 billion in 2025, then increased by 1.11% to $2.6 billion in 2026.
- Business Quant data shows TECH's Total Liabilities at $2.6 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.5 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn | 478.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 478.51 Mn |
| Mar 31, 2026 | 465.30 Mn |
| Dec 31, 2025 | 511.71 Mn |
| Sep 30, 2025 | 560.33 Mn |
| Jun 30, 2025 | 639.06 Mn |
| Mar 31, 2025 | 626.23 Mn |
| Dec 31, 2024 | 591.93 Mn |
| Sep 30, 2024 | 597.37 Mn |
| Jun 30, 2024 | 635.02 Mn |
| Mar 31, 2024 | 706.80 Mn |
| Dec 31, 2023 | 767.19 Mn |
| Sep 30, 2023 | 757.61 Mn |
| Jun 30, 2023 | 672.18 Mn |
| Mar 31, 2023 | 710.01 Mn |
| Dec 31, 2022 | 536.30 Mn |
| Sep 30, 2022 | 599.57 Mn |
| Jun 30, 2022 | 593.79 Mn |
| Mar 31, 2022 | 586.57 Mn |
| Dec 31, 2021 | 602.32 Mn |
| Sep 30, 2021 | 623.23 Mn |